| 2025-12-01 |
详情>>
内部人交易：
Connaughton Bernadette股份减少829.00股
|
| 2025-11-03 |
详情>>
股本变动：
变动后总股本11759.70万股
|
| 2025-11-03 |
详情>>
业绩披露：
2025年三季报(累计)每股收益3.80美元,归母净利润4.58亿美元,同比去年增长49.30%
|
| 2025-11-03 |
财报披露：
美东时间 2025-11-03 盘后发布财报
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益2.32美元,归母净利润2.83亿美元,同比去年增长66.55%
|
| 2025-05-06 |
详情>>
业绩披露：
2025年一季报每股收益0.96美元,归母净利润1.18亿美元,同比去年增长53.72%
|
| 2025-03-18 |
股东大会：
将于2025-05-01召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors to hold office for a three-year term and until their respective successors are elected and qualified;
2.To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.To transact such other business as may properly come before the Annual Meeting.
|
| 2025-02-18 |
详情>>
业绩披露：
2022年年报每股收益1.48美元,归母净利润2.02亿美元,同比去年增长-49.81%
|
| 2025-02-18 |
详情>>
业绩披露：
2024年年报每股收益3.50美元,归母净利润4.44亿美元,同比去年增长57.71%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益2.42美元,归母净利润3.07亿美元,同比去年增长56.51%
|
| 2024-08-06 |
详情>>
业绩披露：
2023年中报每股收益0.86美元,归母净利润1.14亿美元,同比去年增长38.14%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益1.34美元,归母净利润1.70亿美元,同比去年增长48.70%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益0.61美元,归母净利润7682.30万美元,同比去年增长93.92%
|
| 2024-03-15 |
股东大会：
将于2024-04-25召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors to hold office for a three-year term and until their respective successors are elected and qualified;
2.To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers;
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers;
4.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
5.To transact such other business as may properly come before the Annual Meeting.
|
| 2024-02-20 |
详情>>
业绩披露：
2023年年报每股收益2.13美元,归母净利润2.82亿美元,同比去年增长39.31%
|
| 2023-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益1.48美元,归母净利润1.96亿美元,同比去年增长35.85%
|
| 2023-03-24 |
股东大会：
将于2023-05-05召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to hold office for a three-year term and until their respective successors are elected and qualified;
2.To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers;
3.To approve, by a non-binding advisory vote, the frequency of holding future advisory votes regarding the compensation of our Named Executive Officers;
4.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
5.To transact such other business as may properly come before the Annual Meeting.
|
| 2022-03-25 |
股东大会：
将于2022-05-05召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors to hold office for a three-year term and until their respective successors are elected and qualified;
2.To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.To transact such other business as may properly come before the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-26 |
股东大会：
将于2021-05-05召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors to hold office for a three-year term and until their respective successors are elected and qualified;
2.To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers;
3.To approve the Halozyme Therapeutics, Inc. 2021 Stock Plan;
4.To approve the Halozyme Therapeutics, Inc. 2021 Employee Stock Purchase Plan;
5.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
6.To transact such other business as may properly come before the Annual Meeting.
|
| 2020-03-20 |
股东大会：
将于2020-04-30召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to hold office for a three-year term and until their respective successors are elected and qualified;
2.To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
4.To transact such other business as may properly come before the Annual Meeting.
|
| 2019-11-04 |
复牌提示：
2019-11-04 06:55:12 停牌，复牌日期 2019-11-04 07:30:00
|
| 2019-03-22 |
股东大会：
将于2019-05-02召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors to hold office for a three-year term and until their respective successors are elected and qualified;
2.To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.To approve an amendment to our Certificate of Incorporation to increase our authorized number of shares of common stock from 200,000,000 to 300,000,000;
5.To transact such other business as may properly come before the Annual Meeting.
|
| 2019-03-22 |
股东大会：
将于2019-05-02召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors to hold office for a three-year term and until their respective successors are elected and qualified;
2.To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.To approve an amendment to our Certificate of Incorporation to increase our authorized number of shares of common stock from 200,000,000 to 300,000,000;
5.To transact such other business as may properly come before the Annual Meeting.
|
| 2018-03-22 |
股东大会：
将于2018-05-02召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors to hold office for a three-year term and until their respective successors are elected and qualified;
2.To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
4.To approve amendments to the Halozyme Therapeutics, Inc. 2011 Stock Plan;
5.To transact such other business as may properly come before the Annual Meeting.
|
| 2017-03-24 |
股东大会：
将于2017-05-04召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors to hold office for a three-year term and until their respective successors are elected and qualified;
2.To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers;
3.To approve, by a non-binding advisory vote, the frequency of holding future advisory votes regarding the compensation of our named executive officers;
4.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
5.To transact such other business as may properly come before the Annual Meeting.
|
| 2016-03-23 |
股东大会：
将于2016-05-04召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors to hold office for a three-year term and until their respective successors are elected and qualified;
2.To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
4.To approve amendments to the Halozyme Therapeutics, Inc. 2011 Stock Plan;
5.To approve the Halozyme Therapeutics, Inc. Executive Incentive Plan;
6.To transact such other business as may properly come before the Annual Meeting.
|
| 2015-04-03 |
股东大会：
将于2015-05-06召开股东大会
会议内容 ▼▲
- 1. To elect two Class II directors to hold office for a three-year term and until their respective successors are elected and qualified;
2. To approve, by advisory vote, the compensation of our named executive officers;
3. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015;
4. To approve amendments to the Amended and Restated 2011 Stock Plan;
5. To transact such other business as may properly come before the annual meeting.
|